The added value of modern Decision Support Systems (DSS) against forest fires in a global scale

Forest fires constitute one of the greatest hazards for the viability and sustainable development of forests with consequences both on natural and cultural environment, undermining the economy and the quality of life of local and regional populations. The outbreaks of forest fires could stem from either natural or anthropogenic causes. The latter usually compose the greatest percentage of ignition of forest fires especially at the Mediterranean regions. The best strategic to grapple with forest fires while taking under consideration both functional and economic efficiency is considered of primary importance. To this effect, great share have the usage and adoption of decision support systems (DSS) which contain tools of G.I.S. and satellite technology and function as information systems which support the managers responsible for eliminating the forest fires. DSS make up a valuable tool for prevention and fighting against forest fires and lately they are adopted at growing rate at global level. The basic models-subsystems which comprise the structural elements for confronting forest fires and most DSS use are the following: 1) Retrieval, analysis, update, edit and prediction models of geospatial (geomorphology - topography, socioeconomic and environmental data), meteorological and satellite data, 2) Risk indexes and thematic maps (past fire incidents - records, moisture data etc.) of indigenous vegetation and forest fuel, 3) Fire propagation and behavior models and 4) Utilizing of interactive programs for the preparation, plans establishing, coordination and prompt dispatch of specific forces of the fire department (human force, land or aerial firefighting forces or even a combination). Definitely, the sub-systems of the most DSS can be used independently depending on the main purpose, such as for prevention or suppression procedures; for the financial estimation of the planned mission; for the smoke detection and the prediction of its repercussions on the human health etc. Hence, the paper aims to a comparative assessment of the most contemporary DSS which are in use in different geographic scales -such as national and federal level- as well as to a thorough exploration of the effectiveness and contribution of such systems to the confronting of forest fires

Comparison of the Land Uses and Sustainable Development in Small Islands: The Case of Skiathos Island, Greece

The Island of Skiathos occupies a total area of 50 km2, accounting for 1.6% of the area of the prefecture of Magnesia and 0.28% of the Region of Thessaly, Greece. The land is hilly and can be divided into farmland, meadows, woodlands, land covered by water and land occupied by settlements and roads. Also, a large part is occupied by burnt areas that resulted from the fire of 2007. The aim of this chapter is to present the evolution of existing land uses at the Island of Skiathos during the past decades. With the contribution of Geographic Information Systems (GIS) and the orthophotomaps, the spatial planning of the land uses can be evaluated for all these years and the total area can also be calculated. Our results are important for understanding the impacts of land uses on ecosystems in the frame of sustainable development. There has been no other research regarding land uses in Skiathos Island in the past, and, also, this is the first digitization of the area. Finally, two sustainable spatial development scenarios for the Island of Skiathos are proposed. The first scenario relates to the results obtained from a prediction (application of the model of automatic cellular) while the second scenario refers to a more realistic model of development with focus on environmental protection and sustainable development

Remotely sensed data fusion for spatiotemporal geostatistical analysis of forest fire hazard

Sakellariou, S., Cabral, P., Caetano, M., Pla, F., Painho, M., Christopoulou, O., ... Vasilakos, C. (2020). Remotely sensed data fusion for spatiotemporal geostatistical analysis of forest fire hazard. Sensors (Switzerland), 20(17), 1-20. [5014]. https://doi.org/10.3390/s20175014Forest fires are a natural phenomenon which might have severe implications on natural and anthropogenic ecosystems. Future projections predict that, under a climate change environment, the fire season would be lengthier with higher levels of droughts, leading to higher fire severity. The main aim of this paper is to perform a spatiotemporal analysis and explore the variability of fire hazard in a small Greek island, Skiathos (a prototype case of fragile environment) where the land uses mixture is very high. First, a comparative assessment of two robust modeling techniques was examined, namely, the Analytical Hierarchy Process (AHP) knowledge-based and the fuzzy logic AHP to estimate the fire hazard in a timeframe of 20 years (1996–2016). The former technique was proven more representative after the comparative assessment with the real fire perimeters recorded on the island (1984–2016). Next, we explored the spatiotemporal dynamics of fire hazard, highlighting the risk changes in space and time through the individual and collective contribution of the most significant factors (topography, vegetation features, anthropogenic influence). The fire hazard changes were not dramatic, however, some changes have been observed in the southwestern and northern part of the island. The geostatistical analysis revealed a significant clustering process of high-risk values in the southwestern and northern part of the study area, whereas some clusters of low-risk values have been located in the northern territory. The degree of spatial autocorrelation tends to be greater for 1996 rather than for 2016, indicating the potential higher transmission of fires at the most susceptible regions in the past. The knowledge of long-term fire hazard dynamics, based on multiple types of remotely sensed data, may provide the fire and land managers with valuable fire prevention and land use planning tools.publishersversionpublishe

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

PURPOSE: ATHENA (ClinicalTrials.gov identifier: NCT03522246) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without BRCA1 or BRCA2 (BRCA) mutations or other evidence of homologous recombination deficiency (HRD), or high-risk clinical characteristics such as residual disease. We report the results from the ATHENA-MONO comparison of rucaparib versus placebo. METHODS: Patients with stage III-IV high-grade ovarian cancer undergoing surgical cytoreduction (R0/complete resection permitted) and responding to first-line platinum-doublet chemotherapy were randomly assigned 4:1 to oral rucaparib 600 mg twice a day or placebo. Stratification factors were HRD test status, residual disease after chemotherapy, and timing of surgery. The primary end point of investigator-assessed progression-free survival was assessed in a step-down procedure, first in the HRD population (BRCA-mutant or BRCA wild-type/loss of heterozygosity high tumor), and then in the intent-to-treat population. RESULTS: As of March 23, 2022 (data cutoff), 427 and 111 patients were randomly assigned to rucaparib or placebo, respectively (HRD population: 185 v 49). Median progression-free survival (95% CI) was 28.7 months (23.0 to not reached) with rucaparib versus 11.3 months (9.1 to 22.1) with placebo in the HRD population (log-rank P =.0004; hazard ratio [HR], 0.47; 95% CI, 0.31 to 0.72); 20.2 months (15.2 to 24.7) versus 9.2 months (8.3 to 12.2) in the intent-to-treat population (log-rank P <.0001; HR, 0.52; 95% CI, 0.40 to 0.68); and 12.1 months (11.1 to 17.7) versus 9.1 months (4.0 to 12.2) in the HRD-negative population (HR, 0.65; 95% CI, 0.45 to 0.95). The most common grade ≥ 3 treatment-emergent adverse events were anemia (rucaparib, 28.7% v placebo, 0%) and neutropenia (14.6% v 0.9%). CONCLUSION: Rucaparib monotherapy is effective as first-line maintenance, conferring significant benefit versus placebo in patients with advanced ovarian cancer with and without HRD.Open access articleThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)

PURPOSEATHENA (ClinicalTrials.gov identifier: ) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without BRCA1 or BRCA2 (BRCA) mutations or other evidence of homologous recombination deficiency (HRD), or high-risk clinical characteristics such as residual disease. We report the results from the ATHENA-MONO comparison of rucaparib versus placebo.METHODSPatients with stage III-IV high-grade ovarian cancer undergoing surgical cytoreduction (R0/complete resection permitted) and responding to first-line platinum-doublet chemotherapy were randomly assigned 4:1 to oral rucaparib 600 mg twice a day or placebo. Stratification factors were HRD test status, residual disease after chemotherapy, and timing of surgery. The primary end point of investigator-assessed progression-free survival was assessed in a step-down procedure, first in the HRD population (BRCA-mutant or BRCA wild-type/loss of heterozygosity high tumor), and then in the intent-to-treat population.RESULTSAs of March 23, 2022 (data cutoff), 427 and 111 patients were randomly assigned to rucaparib or placebo, respectively (HRD population: 185 v 49). Median progression-free survival (95% CI) was 28.7 months (23.0 to not reached) with rucaparib versus 11.3 months (9.1 to 22.1) with placebo in the HRD population (log-rank P = .0004; hazard ratio [HR], 0.47; 95% CI, 0.31 to 0.72); 20.2 months (15.2 to 24.7) versus 9.2 months (8.3 to 12.2) in the intent-to-treat population (log-rank P &amp;lt; .0001; HR, 0.52; 95% CI, 0.40 to 0.68); and 12.1 months (11.1 to 17.7) versus 9.1 months (4.0 to 12.2) in the HRD-negative population (HR, 0.65; 95% CI, 0.45 to 0.95). The most common grade &amp; GE; 3 treatment-emergent adverse events were anemia (rucaparib, 28.7% v placebo, 0%) and neutropenia (14.6% v 0.9%).CONCLUSIONRucaparib monotherapy is effective as first-line maintenance, conferring significant benefit versus placebo in patients with advanced ovarian cancer with and without HRD.Funding Agencies|Clovis Oncology Inc.; NIHR Cambridge Biomedical Research Centre; [BRC-1215-20,014]</p